HDAC1/3 dual selective inhibitors — New therapeutic agents for the potential treatment of cancer

Drug Discoveries & Therapeutics

Volumn 8, Issue 5, 2011, Pages 225-228

  Li, Xiaoyang ^a   Xu, Wenfang ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

anticancer agent; Epigenetic; HDAC1 3 selective inhibitors; HDACs; selective HDACIs

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; HUMAN; METABOLISM; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NEOPLASMS;

EID: 84930513407     PISSN: 18817831     EISSN: 1881784X     Source Type: Journal    
DOI: 10.5582/ddt.2014.01034     Document Type: Article

References (13)

1. Kristensen LS, Nielsen HM, Hansen LL. Epigenetics and cancer treatment. Eur J Pharmacol. 2009; 625: 131-142.
2. Gregoretti I, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: Functional implications of phylogenetic analysis. J Mol Biol. 2004; 338: 17-31.
3. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anticancer agents. J Hematol Oncol. 2010; 3: 5.
4. Arts J, King P, Mariën A, et al. JNJ-26481585, a novel “second-generation” oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009; 15: 6841-6851.
5. Bergman JA, Woan K, Perez-Villarroel P, Villagra A, Sotomayor EM, Kozikowski AP. Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth. J Med Chem. 2012; 55: 9891-9899.
6. Gupta PK, Reid RC, Liu L, Lucke AJ, Broomfield SA, Andrews MR, Sweet MJ, Fairlie DP. Inhibitors selective for HDAC6 in enzymes and cells. Bioorg Med Chem Lett. 2010; 20: 7067-7070.
7. Bürli RW, Luckhurst CA, Aziz O, et al. Design, synthesis, and biological evaluation of potent and selective Class IIa histone deacetylase (HDAC) inhibitors as a potential therapy for Huntington's disease. J Med Chem. 2013; 56: 9934-9954.
8. Santo L, Hideshima T, Kung A L, et al. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY21215, in combination with bortezomib in multiple myeloma. Blood. 2012; 119: 2579-2589.
9. Lee MJ, Kim YS, Kummar S, Giaccone G, Trepel JB. Histone deacetylase inhibitors in cancer therapy. Curr Opin Oncol. 2008; 20: 639-649.
10. Moradei OM, Mallais TC, Frechette S, et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. J Med Chem. 2007; 50: 5543-5546.
11. Methot JL, Chakravarty PK, Chenard M, et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1: 2). Bioorg Med Chem Lett. 2008; 18: 973-978.
12. Li X, Inks ES, Li X, Hou J, Chou CJ, Zhang J, Jiang Y, Zhang Y, Xu W. Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity. J Med Chem. 2014; 57: 3324-3334.
13. Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol. 2005; 47: 3797-3804.